Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Services Industry Analysis

UpdatedSep 14, 2025
DataAggregated Company Financials
Companies159
  • 7D4.0%
  • 3M3.0%
  • 1Y-24.3%
  • YTD-8.0%

The Healthcare Services industry is up 4.0% in the last week, with UnitedHealth Group up 12%. In the same time, Humana was down 10%. In the past year, the industry is down 24%. Earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the U.S. Healthcare Services Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 14 Sep 2025US$903.4bUS$2.1tUS$49.4b21.3x18.3x0.4x
Tue, 12 Aug 2025US$766.9bUS$2.1tUS$49.1b20.5x15.6x0.4x
Thu, 10 Jul 2025US$854.5bUS$2.1tUS$52.7b22x16.2x0.4x
Sat, 07 Jun 2025US$861.3bUS$2.1tUS$52.5b21.3x16.4x0.4x
Mon, 05 May 2025US$913.9bUS$1.7tUS$50.8b22.3x18x0.5x
Wed, 02 Apr 2025US$1.0tUS$1.7tUS$41.6b24.1x24.9x0.6x
Fri, 28 Feb 2025US$967.2bUS$1.7tUS$41.6b24.1x23.2x0.6x
Sun, 26 Jan 2025US$1.1tUS$2.0tUS$41.9b23.1x25.8x0.5x
Tue, 24 Dec 2024US$998.9bUS$2.0tUS$41.4b22x24.1x0.5x
Thu, 21 Nov 2024US$1.1tUS$2.0tUS$41.4b25.8x27x0.6x
Sat, 19 Oct 2024US$1.2tUS$1.9tUS$43.3b25.5x26.8x0.6x
Mon, 16 Sep 2024US$1.2tUS$1.9tUS$43.3b27.5x28.3x0.6x
Wed, 14 Aug 2024US$1.2tUS$1.9tUS$43.2b28.6x27x0.6x
Fri, 12 Jul 2024US$1.1tUS$1.9tUS$43.4b24.7x25.1x0.6x
Sun, 09 Jun 2024US$1.1tUS$1.9tUS$43.4b26.5x25.2x0.6x
Tue, 07 May 2024US$1.1tUS$1.9tUS$42.3b27x25.8x0.6x
Thu, 04 Apr 2024US$1.1tUS$1.8tUS$49.6b26.2x21.8x0.6x
Sat, 02 Mar 2024US$1.1tUS$1.8tUS$49.8b24.1x22.3x0.6x
Mon, 29 Jan 2024US$1.1tUS$1.8tUS$50.0b23.5x22.4x0.6x
Wed, 27 Dec 2023US$1.1tUS$1.8tUS$51.2b23.3x22.4x0.6x
Fri, 24 Nov 2023US$1.1tUS$1.8tUS$51.1b22.6x22.4x0.6x
Sun, 22 Oct 2023US$1.1tUS$1.8tUS$47.1b22.5x24.1x0.6x
Tue, 19 Sep 2023US$1.1tUS$1.8tUS$46.9b21.5x23.2x0.6x
Thu, 17 Aug 2023US$1.1tUS$1.8tUS$46.7b22.4x24.1x0.6x
Sat, 15 Jul 2023US$1.1tUS$1.7tUS$46.5b23.6x23.6x0.6x
Mon, 12 Jun 2023US$1.1tUS$1.7tUS$45.8b22.5x24.4x0.7x
Wed, 10 May 2023US$1.1tUS$1.7tUS$45.8b22.4x24.1x0.6x
Fri, 07 Apr 2023US$1.1tUS$1.4tUS$43.7b23.8x25.3x0.8x
Sun, 05 Mar 2023US$1.1tUS$1.4tUS$44.2b22.2x24.5x0.8x
Tue, 31 Jan 2023US$1.1tUS$1.4tUS$44.8b21x25x0.8x
Thu, 29 Dec 2022US$1.2tUS$1.4tUS$44.4b21x26.6x0.8x
Sat, 26 Nov 2022US$1.2tUS$1.4tUS$44.4b20.8x27.2x0.9x
Mon, 24 Oct 2022US$1.2tUS$1.4tUS$46.7b19.6x25.2x0.8x
Wed, 21 Sep 2022US$1.2tUS$1.4tUS$46.1b18.7x25.7x0.9x
Price to Earnings Ratio

25.7x


Total Market Cap: US$1.2tTotal Earnings: US$46.1bTotal Revenue: US$1.4tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Services Industry Price to Earnings3Y Average 23.7x202320242025
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 18.3x which is lower than its 3-year average PE of 23.7x.
  • The industry is trading close to its 3-year average PS ratio of 0.63x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 2.3% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.73%
Healthcare-0.27%
Healthcare Services3.96%
Managed Healthcare7.45%
Healthcare Distributors2.89%
Healthcare Services0.53%
Healthcare Facilities-1.81%
Industry PE
  • Investors are most optimistic about the Healthcare Distributors industry even though it's trading below its 3-year average PE ratio of 37.7x.
    • Analysts are expecting annual earnings growth of 13.7%, which is higher than its past year's earnings growth of 6.3% per year.
  • Investors are most pessimistic about the Managed Healthcare industry, which is trading below its 3-year average of 22.5x.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 20% over the next 5 years.
  • This is better than its past earnings decline of 0.03% per year.
  • In contrast, the Managed Healthcare industry is expected to see its earnings grow by 7.5% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
UNH UnitedHealth GroupUS$352.5111.8%
+US$33.6b		-40.7%PE15x
MCK McKessonUS$711.423.5%
+US$3.0b		37.1%PE28x
CNC CenteneUS$33.2614.8%
+US$2.1b		-55.9%PE8x
COR CencoraUS$302.523.4%
+US$1.9b		26.1%PE30.9x
HIMS Hims & Hers HealthUS$55.5014.6%
+US$1.6b		234.9%PE64.8x

Latest News

GH
US$54.90
Guardant Health
7D
-8.7%
1Y
104.9%
CNC
US$33.26
Centene
7D
14.8%
1Y
-55.9%

Centene Corporation's (NYSE:CNC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Sep 12
Centene Corporation's (NYSE:CNC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
HIMS
US$55.50
Hims & Hers Health
7D
14.6%
1Y
234.9%
HCA
US$405.13
HCA Healthcare
7D
-3.7%
1Y
2.6%
UNH
US$352.51
UnitedHealth Group
7D
11.8%
1Y
-40.7%

Medicare Shifts And Digital Tools Will Secure Future Performance

Analysts raised UnitedHealth Group’s price target to $333.42, citing improved earnings visibility from strong Medicare Advantage Star ratings, reaffirmed 2025 guidance, and confidence in multi-year margin recovery, despite ongoing regulatory and DOJ-related risks. Analyst Commentary Bullish analysts raised price targets following UnitedHealth's better-than-expected preliminary 2026 Medicare Advantage Star ratings (78% of members in 4+ Star plans), which provided improved earnings visibility and alleviated investor concerns over regulatory headwinds.
BTSG
US$26.45
BrightSpring Health Services
7D
9.6%
1Y
91.0%

Specialty Pharmacy And Home Health Expansion Will Create Lasting Opportunity

Analysts modestly raised BrightSpring Health Services’ price target to $29.12, reflecting confidence in specialty pharmacy and generic growth catalysts outweighing home health reimbursement concerns. Analyst Commentary Bullish analysts cite durable growth expected from Limited Distribution Drugs (LDDs) and generic conversions, which are anticipated to drive stronger adjusted EBITDA in the second half of 2025 and sustain growth into 2026.
NAKA
US$2.78
Kindly MD
7D
-31.9%
1Y
118.9%

Kindly MD - Stuck In A Highly Dilutive Cycle

Sep 08
COR
US$302.52
Cencora
7D
3.4%
1Y
26.1%
ENSG
US$167.99
Ensign Group
7D
-3.4%
1Y
10.0%

Rising US Eldercare Demand And Acquisitions Will Drive Expansion

With no changes observed in either Ensign Group’s future P/E ratio or net profit margin, the consensus analyst price target remains stable at $174.67. What's in the News Ensign Group settled a whistleblower lawsuit for over $47.3 million, resolving allegations of nationwide Medicare and Medicaid fraud, kickbacks, and violations of federal and state laws, as well as breaching a prior Corporate Integrity Agreement.
HUM
US$276.44
Humana
7D
-10.2%
1Y
-14.0%

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana’s modestly higher fair value reflects improving investor sentiment, positive management commentary on future plan positioning, raised earnings guidance, and incremental legislative benefits, offset by some caution around interest rates and policy uncertainty, resulting in the consensus analyst price target rising slightly from $293.05 to $294.86. Analyst Commentary Improved investor sentiment and sector group valuations suggest estimates may have bottomed, with upcoming catalysts including government budget deals, Medicare Advantage and ACA pricing, and star ratings for future plans.
DVA
US$133.17
DaVita
7D
-3.4%
1Y
-18.6%

Aging Population And AI Will Reshape Dialysis Care

Analysts have revised their outlook on DaVita to reflect lower treatment growth, reduced revenue per treatment, and ongoing operational challenges stemming from cyberattack disruptions, resulting in a consensus price target that remains unchanged at $153.50. Analyst Commentary Bearish analysts revised down treatment growth expectations due to higher missed treatment rates stemming from cyberattack disruptions.
CVS
US$74.98
CVS Health
7D
1.6%
1Y
29.3%

Digital Health Transformation And Integrated Care Will Expand Reach

Despite ongoing external risks and policy uncertainty, analysts remain constructive on CVS Health, citing strong recent execution, conservative guidance with potential for upside, and compelling valuation, resulting in the consensus price target holding steady at $81.57. Analyst Commentary Bullish analysts cite strong recent execution and early signs that fixes in the healthcare benefits segment are proving effective, supporting above-consensus earnings growth projections.
ELV
US$311.76
Elevance Health
7D
-0.6%
1Y
-43.4%

AI-Enabled Analytics And Value-Based Care Will Ensure Future Stability

Following disappointing Q2 results and a significant EPS guidance cut for 2025, analysts remain cautious on Elevance Health due to earnings uncertainty and operational risks—despite some offsetting segmental strengths and longer-term positives—resulting in an unchanged consensus price target of $368.44. Analyst Commentary Bearish analysts lowered price targets following Elevance Health’s Q2 report, citing a larger-than-expected EPS guidance cut for 2025, lingering questions about the true earnings floor, and persistent volatility in cost trends.
CI
US$302.76
Cigna Group
7D
-0.8%
1Y
-17.0%
MCK
US$711.42
McKesson
7D
3.5%
1Y
37.1%
CAH
US$152.24
Cardinal Health
7D
1.8%
1Y
34.5%